Market cap
$19.8M

Aytu BioPharma Inc. (AYTU) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 12 wire items for AYTU, including 6 SEC filings, 3 market updates and 1 press release or news item. The most recent was published Nov 17, 2026.

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

Financial highlights

Full financials
Revenue, TTM
$58.52M
Revenue growth
-8.1%
Net income, TTM
-$20.10M
Net margin
-34.3%
Cash
$25.49M

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

News · 26 weeks27+1000%
2026-05-24: 02026-05-31: 12026-06-07: 02026-06-14: 02026-06-21: 12026-06-28: 02026-07-05: 02026-07-12: 02026-07-19: 02026-07-26: 82026-08-02: 02026-08-09: 12026-08-16: 02026-08-23: 02026-08-30: 02026-09-06: 02026-09-13: 12026-09-20: 32026-09-27: 02026-10-04: 02026-10-11: 02026-10-18: 12026-10-25: 12026-11-01: 02026-11-08: 22026-11-15: 8
2026-05-242026-11-15
Mix1690d
  • SEC Filings8(50%)
  • Market5(31%)
  • Other1(6%)
  • M&A1(6%)
  • Analyst1(6%)
Activity · 52 weeks4725 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

AYTU FAQ

10 questions
  • What does Aytu BioPharma Inc. do?
    Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal...
  • What is the latest news on AYTU?
    In the last 30 days Quantisnow tracked 12 wire items for AYTU: 6 SEC filings, 3 market updates, 1 press release or news item and 1 M&A update. The most recent was published on November 17, 2026.
  • What is AYTU revenue?
    Aytu BioPharma Inc. (AYTU) reported $58.52M of revenue for the twelve months ended Sep 30, 2026. That is down 8.1% from the year before. Revenue for fiscal 2026 was $57.57M.
  • Is AYTU profitable?
    No. Aytu BioPharma Inc. reported a net loss of $20.10M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does AYTU have?
    Aytu BioPharma Inc. reported $25.49M in cash and cash equivalents and $10.51M of debt on its most recent balance sheet in SEC filings.
  • Where does AYTU stock trade?
    Aytu BioPharma Inc. (AYTU) is listed on NASDAQ.
  • What sector and industry is AYTU in?
    Aytu BioPharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • What are analysts saying about AYTU?
    Across the last 3 analyst actions on Aytu BioPharma Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Lake Street: Hold with a $2.70 price target on 2026-11-17. Recent price targets range from $2.70 to $12.00.
  • What companies are similar to AYTU?
    Notable peers in the same industry include ZVRA (Zevra Therapeutics Inc.), SUPN (Supernus Inc.), ETON (Eton Pharmaceuticals Inc.), COLL (Collegium Pharmaceutical Inc.), HRMY (Harmony Biosciences Holdings Inc.). Compare AYTU side-by-side with any of them on Quantisnow.
  • How can I track AYTU on Quantisnow?
    Quantisnow aggregates Aytu BioPharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AYTU to receive live email and push alerts on every new disclosure.